Cizzle Biotechnology (LON:CIZ) has taken a critical step toward getting its early lung cancer blood test into UK hospitals, signing a letter of intent with a major diagnostics partner working alongside the NHS. In this interview, Executive Chairman Dr Allan Syms outlines how this move supports the NHS’s early detection strategy, complements their active US licensing model, and accelerates the test’s return to the UK — where the underlying science was first developed.
Key Moments
- 00:12 – LOI signed with NHS-linked diagnostics partner
- 01:01 – CIZ1B test’s role in global licensing strategy
- 02:29 – Test’s UK research origins and commercial goal
- 03:37 – Alignment with NHS early detection ambitions
- 04:58 – How early diagnosis can reduce cancer fatalities
- 06:39 – Validation now underway in UK commercial labs
- 08:03 – US deal comparison and licensing model
- 09:20 – Pathway to European, Asian, and LATAM markets
Cizzle Biotechnology is a UK-based diagnostics developer focused on early-stage cancer detection through its proprietary CIZ1B blood test.
